source
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.BioPharma Dive · 2mo ago↗ source
- STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and moreAn FDA proposal to remove references to “gender” from its regulations sparked concerns about unintended consequences on researchSTAT · 2mo ago↗ source
- Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCLLore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.onclive · 2mo ago↗ source